News About: Pharm. Industry
Industry expert sees combination drugs as new growth engine
Combination products will turn out to be tremendously lucrative as one of strategic items once they receive formal approval from a reliable drug-licensing agency and are put onto the market, according to a local marke...
Handk to introduce new anticancer drug
Handok Pharm says it has recently signed a licensing agreement with the U.S. based Spectrum Pharmaceuticals, Inc., a commercial stage biotechnology company with a primary focus in oncology, to develop and market Spect...
Allergan Korea launches new treatment for hypotrichosis of the eyelashes
Allergan Korea said it has launched LATISSE™ (bimatoprost ophthalmic solution) 0.03% as a novel treatment for hypotrichosis of the eyelashes.
Eyelash hypotrichosis is another name for having inadequate or not enoug...
Korean drugmakers issue signature campaign against low-priced drug incentive system
The Korea Pharmaceutical Manufacturer Association said on November 20 it delivered its petition letter to Chong Wa Dae in protest of the health ministry's plan to offer an incentive to hospitals who will purchase low-...
Green Cross seeking free supply of Peramir
Green Cross Corporation is considering offering an investigational antiviral drug Peramivir intravenous (IV) for the treatment of certain adult and pediatric patients with confirmed or suspected H1N1 influenza infecti...
Korea Bone Bank selected as Asia’s promising enterprise
ePlanet Ventures, the world’s leading global venture capital firm headquartered in Silicon Valley, California, announced on November 20 that Korea Bone Bank was selected as one of the most promising corporations with ...
Wholesalers issue ultimatum to expand direct dealing
The Korea Association of Pharmaceutical Wholesaler says it delivered an official letter, asking several multinational companies to respond to their request for direct transaction by November 17.
These companies inc...
Rising development costs make biosimilar market entry a difficult proposition
Biosimilar development is riddled with complexities, ranging from regulatory, to manufacturing to marketing, and is one of the most expensive propositions in the pharmaceutical industry, according to market experts.
...
Key success factors in emerging biosimilar markets
Despite the fact that the biosimilars market presents a multitude of opportunities, biosimilar development is a risk-fraught activity that demands significant resources in R&D, manufacturing expertise, regulatory know...
Zydena’s once-daily-dosing is effective
Dong-A Pharmaceutical Co. says it has completed a 240 Korean patient once-a-day dosing clinical study of udenafil, its new long acting phosphodiesterase type 5 (PDE-5) inhibitor for erectile dysfunction (ED).
Follo...
